EUCTR2004-002355-14-DE进行中（未招募）不适用
A randomized, multicenter, open phase III study comparing the postoperative use of zoledronic acid versus no treatment in patients with histological tumor residuals after preoperative anthracycline and taxane containing chemotherapy for primary breast cancer (NEO-ADJUVANT TRIAL ADD-ON) - NATA
GBG Forschungsgesellschaft mbH0 个研究点目标入组 654 人开始时间: 2004年10月8日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 654
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •- Written informed consent must be obtained and documented according to the local regulatory requirements prior to beginning specific protocol procedures;
- •- Complete baseline documentation sent to GBG;
- •- Prior preoperative chemotherapy for at least 4 cycles, of which at least two must contain a taxane and an anthracycline given within a clinical trial approved by the protocol board;
- •- Completely resected unilateral or bilateral primary carcinoma of the breast with histologically detectable tumor residuals (ypT1-4) and or histologically confirmed involvement of axillary nodes (ypN1-3). Complete axillary clearance is mandatory, sentinel node biopsy alone is not allowed in node positive cases;
- •- A maximum interval from date of axillary surgery to entering this trial of 3 years;
- •- Age 18 years or older;
- •- Karnofsky index >= 70%;
- •- Life expectancy of at least 10 years, disregarding the diagnosis of cancer;
- •- No clinical evidence of local recurrence or distant metastases. Complete staging work-up within 3 months prior to registration. All patients must have (bilateral) mammography or breast MRI, breast ultrasound, chest X-ray, ultrasound or CT scan of the liver, and bone scan (within 8 months). In case of a positive bone scan, bone X-ray is mandatory. Other tests may be performed as clinically indicated;
- •- Adequate renal and hepatic function (serum creatinine, bilirubin, and transaminases within 1.5 × upper normal range);
- •- Tissue block centrally available for further biological tests;
- •- Patients must be available and compliant for treatment and follow-up. Patients registered on this trial must be treated and followed up at the participating center.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Known hypersensitivity reaction to the investigational compound;
- •- Prior postoperative chemotherapy;
- •- Prior treatment with bisphosphonates since breast cancer surgery;
- •- Pregnant or lactating patients. Patients of childbearing potential must have a negative pregnancy test (urine or serum) within 14 days prior to registration and must implement adequate non-hormonal contraceptive measures during study treatment;
- •- History of diseases with influence on bone metabolism, such as Paget’s disease of bone and primary hyperparathyroidism or osteoporosis requiring treatment at the time of study entry or considered likely to become necessary within the six months
- •- Other serious illness or medical condition that may interfere with the understanding and giving of informed consent and the conduct of the study
- •- Prior or concomitant secondary malignancy (except non-melanomatous skin cancer or carcinoma in situ of the uterine cervix)
- •- Concurrent treatment with other experimental drugs or any other anti-cancer therapy;
- •- Serum creatinine >= 3 mg/dl (265 micromol/L)
- •- Corrected (adjusted for serum albumin) serum calcium concentration < 8.0 mg/dl (2.00 mmol/L) or >= 12.0 mg/dl (3.00 mmol/L)
- •- Concurrent treatment with sex hormones. Prior treatment must be stopped before study entry;
- •- Male patients.
研究者
相似试验
进行中（未招募）
不适用
eo-Adjuvant Trial Add-OPatients with histological tumor residuals after preoperative anthracycline and taxane containing chemotherapy for primary breast cancerEUCTR2004-002355-14-ATGBG Forschungsgesellschaft mbH654
进行中（未招募）
1 期
Immunogenicity and safety study of GlaxoSmithKline (GSK) Biologicals’ Boostrix™ vaccine and the Chinese DT vaccine, when administered as booster vaccination in healthy children aged 6-8 years.Healthy volunteers (Immunisation against diphtheria, tetanus and pertussis)MedDRA version: 19.0Level: SOCClassification code 10021881Term: Infections and infestationsSystem Organ Class: 10021881 - Infections and infestationsEUCTR2016-000644-34-Outside-EU/EEAGlaxoSmithKline Biologicals660
已完成
不适用
Phase III Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced NeutropeniaNeoplasmsKCT0000518Dong-A Pharm74
进行中（未招募）
1 期
A phase IIIb open, randomized multi-center study to evaluate the immunogenicity and safety of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine when administered intramuscularly according to an alternative dosing schedule at 0, 1 and 12 months as compared to the standard dosing schedule at 0, 1 and 6 months in young healthy female subjects aged 15-25 years. - HPV-044 PRIFor active immunization of females from the age of 10 years onwards to prevent incident and persistent infections, cytological abnormalities and cervical neoplasia (CIN), CIN 1 and pre-cancerous lesions (CIN 2 and CIN 3), caused by oncogenic human papillomavirus (HPV) types 16 and 18.EUCTR2007-003256-11-SKGlaxoSmithKline Biologicals800
进行中（未招募）
不适用
A phase IIIb open, randomized multi-center study to evaluate the immunogenicity and safety of GSK Biologicals HPV-16/18 L1 VLP AS04 vaccine when administered intramuscularly according to an alternative dosing schedule at, 0, 1 and 12 months as compared to the standard dosing schedule at 0, 1 and 6 months in young healthy female subjects aged 15-25 years. - Immunogenicity and Safety Study of GSK Biologicals...For active immunization of females from the age of 10 years onwards to prevent incident and persistent infections, cytological abnormalities and cervical neoplasia (CIN), CIN 1 and pre-cancerous lesions (CIN 2 and CIN 3), caused by oncogenic human papillomavirus (HPV) types 16 and 18.MedDRA version: 6.1Level: HLTClassification code 10029109EUCTR2007-003256-11-ITGLAXO SMITHKLINE800